NASDAQ · CSTL
Castle Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CSTL: Nov 05, 2026
Castle Biosciences, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.38. The reported EPS for the same quarter last year was $-0.02.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Dec 2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Mar 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Jun 2027 | $-0.25 | $-0.25 | $-0.25 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · MarketBeat · The Motley Fool- RTTNews · Sep 28, 2:21 PM EDTCastle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients(RTTNews) – Castle Biosciences, Inc. (CSTL) announced publication of a study showing that its TissueCypher Barrett's Esophagus Test helped guide risk-aligned management decisions in patients with non-dysplastic Barrett's esophagus (NDBE).
- Zacks · Aug 28, 12:00 PM EDTCastle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should KnowDoes Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Aug 25, 9:55 AM EDTDoes Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- RTTNews · Aug 17, 12:25 PM EDTCastle Biosciences Approved For Dual Listing On Nasdaq Texas(RTTNews) – Castle Biosciences, Inc. (CSTL), a diagnostics company developing innovative tests to guide patient care, announced that its common stock has been approved for a dual listing on Nasdaq Texas, while maintaining its primary listing on The Nasdaq Global Market under the
- MarketBeat · Aug 13, 1:01 AM EDTCastle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain TractionCastle Biosciences (NASDAQ:CSTL) reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes. Stokes said the company’s DecisionDx-
- The Motley Fool · Aug 7, 9:48 PM EDTCastle Biosciences (CSTL) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Jul 30, 6:04 PM EDTCastle Biosciences Q2 Earnings Call HighlightsCastle Biosciences (NASDAQ:CSTL) reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported results. The company raised its full-year revenue outlook to $365 million to $375 mill
- Zacks · Jul 30, 6:00 PM EDTCastle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue EstimatesCastle Biosciences (CSTL) delivered earnings and revenue surprises of +84.09% and +18.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 6, 6:30 PM EDTCastle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue EstimatesCastle Biosciences (CSTL) delivered earnings and revenue surprises of +12.50% and +2.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- The Motley Fool · May 6, 6:29 PM EDTCastle (CSTL) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · May 6, 12:06 PM EDTAlkermes' Q1 Earnings & Revenues Beat Estimates, Stock RisesALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.
- Zacks · May 6, 12:01 PM EDTOCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress OutlookOcugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Castle Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.